title: Liver support therapy with molecular adsorbents recirculating system in liver failure: a summary of 252 cases from 14 centers in China.
abstract: BACKGROUND
  A liver support therapy, named molecular adsorbents recirculating system (MARS), has been used for more than 700 liver failure patients in China. We made here a summary to evaluate the effects of MARS treatment in different applications with emphasis on hepatitis B virus (HBV) based liver failure.
  
  
  METHODS
  This report analyzed data of 252 patients (mean age (44.9+/- 12.7) years) in three groups: acute severe hepatitis (ASH), subacute severe hepatitis (SSH) and chronic severe hepatitis (CSH). The largest group was CSH (156 patients, 61.9%), and 188 patients (74.6%, 188/252) were infected with HBV.
  
  
  RESULTS
  MARS treatments were associated with significant reduction of albumin bound toxins and water-soluble toxins. Most of the patients showed a positive response with a significant improvement of multiple organ function substantiated by a significant increase in prothrombin time activity (PTA) and median arterial pressure (MAP). There was a decrease in hepatic encephalopathy (HE) grade and Child-Turcotte-Pugh (CTP) scale. Thirty-nine of 188 HBV patients (20.7%) dropped out of the commendatory consecutive therapy ending with lower survival of 43.6% while the rest of the 149 patients had a survival rate of 62.4%. Survival within the ASH and SSH groups were 81.2% and 75.0%, respectively. In the CSH group, end stage patients were predominant (65/151, 43%), whereas the early and middle stage patients had a better prognosis: early stage survival, including orthotopic liver transplantation (OLT) survival of 91.7%, middle stage survival of 75%, end stage survival of 33.8%.
  
  
  CONCLUSIONS
  MARS continues to be the most favorable extracorporeal treatment for liver support therapy in China for a wide range of conditions, including the majority of hepatitis B related liver failure conditions. The appropriate application of MARS for the right indications and stage of hepatic failure, as well as the fulfillment of prescribed treatments, will lead to the optimal therapeutic result.
authors.affiliation: Therapeutic Blood Purification Research Center, University of Rostock, Germany. minminwang@yahoo.com.cn
authors.forename: Min-min
authors.initials: MM
authors.lastname: Wang
authors.forename: Shi-jun
authors.initials: SJ
authors.lastname: Chen
authors.forename: Qi-fa
authors.initials: QF
authors.lastname: Ye
authors.forename: Yi-jun
authors.initials: YJ
authors.lastname: Yang
authors.forename: Shi-bin
authors.initials: SB
authors.lastname: Chen
authors.forename: Xin-min
authors.initials: XM
authors.lastname: Zhou
authors.forename: Li-min
authors.initials: LM
authors.lastname: Guo
authors.forename: Yue-xin
authors.initials: YX
authors.lastname: Zhang
authors.forename: Xiao-qiang
authors.initials: XQ
authors.lastname: Ding
authors.forename: Xiao-bin
authors.initials: XB
authors.lastname: Hu
authors.forename: Hong-tao
authors.initials: HT
authors.lastname: Luo
authors.forename: Yi-he
authors.initials: YH
authors.lastname: Liu
authors.forename: Wen-ya
authors.initials: WY
authors.lastname: Wang
mesh_terms: D006801:Humans; D017093:Liver Failure / Q000401:mortality / Q000628:therapy*; D006435:Renal Dialysis; D016060:Sorption Detoxification / Q000009:adverse effects / Q000379:methods*